基于MRI新辅助治疗后内乳淋巴结反应指导乳腺癌术后内乳淋巴结放疗加量
该回顾性研究纳入208例基线临床阳性内乳淋巴结乳腺癌患者,评估MRI评估的新辅助治疗后内乳淋巴结临床完全缓解(icCR)能否指导反应适应性内乳淋巴结加量。中位随访36个月,总体队列中内乳淋巴结加量未显著改善无病生存(DFS),但加量与icCR状态存在显著交互作用;未达icCR者加量后DFS改善,达icCR者无显著获益。
核心结论
- 未达icCR的患者接受内乳淋巴结加量后DFS改善,而达icCR的患者无明确获益。
- 新辅助治疗后icCR状态可作为选择反应适应性术后内乳淋巴结放疗加量的潜在指标,有待前瞻性验证。
研究设计与样本
- 回顾性研究纳入208例基线临床阳性内乳淋巴结的乳腺癌患者。
- 采用逆概率治疗加权(IPTW)平衡所选基线特征,并以含交互项的IPTW加权Cox比例风险模型评估icCR状态的效应修饰。
关键数值与推荐
- 基线临床阳性内乳淋巴结定义为入组条件。
- icCR由MRI评估新辅助治疗后内乳淋巴结临床完全缓解状态确定。
临床怎么用
- 对新辅助治疗后MRI评估未达icCR的内乳淋巴结阳性乳腺癌患者,可考虑术后内乳淋巴结放疗加量以改善DFS。
- 对达icCR的患者,内乳淋巴结加量未见明确DFS获益,选择时需权衡治疗相关毒性。
局限性
- 本研究为回顾性设计,结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A radiation therapy boost to the internal mammary nodes (IMNs) is often recommended for patients with breast cancer and clinically positive IMNs at baseline, but it may increase treatment-related toxicity. Given the widespread use of neoadjuvant therapy (NAT), we investigated whether magnetic resonance imaging-assessed IMN clinical complete response (icCR) after NAT could inform response-adapted IMN boost strategies. METHODS AND MATERIALS: This retrospective study included 208 patients with clinically positive IMNs at baseline. The association between an IMN boost and outcomes was evaluated in the overall cohort and in subgroups defined by magnetic resonance imaging-assessed post-NAT icCR status. Inverse probability of treatment weighting (IPTW) was used to improve balance in selected measured baseline characteristics and reduce observed treatment selection bias. Effect modification by icCR status was assessed using IPTW-weighted Cox proportional hazards models with an interaction term. RESULTS: At a median follow-up of 36 months, an IMN boost was not associated with a significant improvement in disease-free survival (DFS) in the overall cohort (IPTW-adjusted hazard ratio [HR], 0.66; 95% CI, 0.32-1.39; P = .277). However, a significant interaction was observed between IMN boost and icCR status (P for interaction = .042). In subgroup analyses, an IMN boost was associated with improved DFS in patients without icCR (IPTW-adjusted HR, 0.36; 95% CI, 0.14-0.93; P = .034), whereas no significant improvement in DFS was observed among patients who achieved icCR (IPTW-adjusted HR, 1.13; 95% CI, 0.47-2.74; P = .781). CONCLUSIONS: In this study, patients without icCR showed improved DFS with an IMN boost, whereas those who achieved icCR showed no clear benefit. These findings support further evaluation of post-NAT icCR status as a potential indicator for selecting response-adapted postoperative IMN radiation therapy boost and warrant prospective validation.
引用
- Peng Y, Zhang S, Tie J, et al. Magnetic Resonance Imaging-Based Internal Mammary Node Response After Neoadjuvant Therapy to Guide Postoperative Internal Mammary Node Radiation Therapy Boost in Breast Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42628809. doi:10.1016/j.ijrobp.2026.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。